Amgen announced the release of AmgenNow, a new direct-to-patient program starting with Repatha® (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial. https://www.coherentmarketinsights.com/news/amgen-unveiled-amgennow-direct-access-to-repatha-1642